Radium-223 Gets Early FDA Nod for Bone Mets in Castration-Resistant Prostate Cancer

Radium-223 dichloride (Xofigo) received FDA approval for the treatment of symptomatic metastatic castration-resistant prostate cancer that has metastasized to the bone but no other organs.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news